No Data
No Data
Breaking Barriers: Immunic CSO Marks International Day of Women and Girls in Science | NASDAQ:IMUX
Immunic Management to Meet With Piper Sandler
Immunic to Participate in Investor and Scientific Conferences in February
Leerink Partners Maintains Immunic(IMUX.US) With Buy Rating, Maintains Target Price $5
Promising Outlook for Immunic's VidoCa in PMS: Favorable Risk/Reward and Key Metrics Drive Buy Rating
Immunic Eyes Key Data Readout From Multiple Sclerosis Trial in 2025 | NASDAQ:IMUX